Company: UFPT
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001171843-25-002638
Chunk: 22

Company: UFP TECHNOLOGIES INC
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 22
---
 | CryoLife, Inc. (now Artivion) | • | OraSure Technologies, Inc. |
| • | AngioDynamics Inc        | • | Cutera, Inc.                  | • | Orthofix Medical, Inc.     |
| • | Anika Therapeutics, Inc. | • | DMC Global, Inc.              |   |                            |
| • | Atrion Corp              | • | Integer Holdings Corp         |   |                            |
| • | Avanos Medical, Inc.     | • | Lantheus Holdings, Inc.       |   |                            |

In 2024, the Compensation Committee engaged Pearl Meyer, a national compensation consulting firm, to perform an updated comprehensive comparative market study of the compensation programs offered to peer company executives and directors, and to provide recommendations on the Company’s executive compensation. The Compensation Committee used this information to establish base pays and other components of compensation for executive and director compensation for fiscal 2025. The competitive assessment done by Pearl Meyer included a survey of the following 19 companies*:

| • | Avanos Medical, Inc          | • | AtriCure, Inc.             | • | Integra Life Sciences Holding Corp. |
| • | Integer Holdings Corporation | • | Glaukos Corporation        | • | STAAR Surgical Company              |
| • | Orthofix Medical, Inc.       | • | Haemonetics Corporation    | • | Sotera Health Company               |
| • | 10X Genomics, Inc.           | • | Inari Medical, Inc.        | • | Transmedics Group, Inc.             |
| • | Atrivion, Inc.               | • | CONMED Corporation         | • | Novanta, Inc.                       |
| • | Azenta, Inc.                 | • | iRhythm Technologies, Inc. | • | Osi Systems, Inc.                   |
| • | Alphatec Holdings, Inc.      |   |                            |   |                                     |

*Our Compensation Committee reviews our peer group approximately every three years to ensure that our peer group is reasonably comparable to our market cap, revenue, employee base, geographical footprint, and industry in which we operate.

Principal Elements of the 2024 Compensation Program

There were five principal elements of compensation for the named executive officers during fiscal 2024:

| • | Base salary; |

| • | Stock grant (Chief Executive Officer only); |

| • | Performance‑based cash incentive bonus;